PIONEERING CELL THERAPIES
Live / Registered — Registered — Section 8 accepted (as of 20 Jun 2026)
What this means for you
Registered since 18 Feb 2020. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 18 Feb 2030: the §8 & §9 renewal).
Record
- Serial number
- 87543744
- Registration number
- 5991584
- Mark type
- Word mark
- Filed
- 26 Jul 2017
- Published for opposition
- 25 Dec 2018
- Registered
- 18 Feb 2020
- Next maintenance filing
- §8 & §9 renewal, due by 18 Feb 2030 (grace period to 18 Aug 2030)
Goods and services
- Class 042 — Scientific and technological services: Product research and development; Scientific research for medical purposes in the field of cell therapies
Owner
- CellTrans Inc., Chicago, IL, US
- CellTrans Inc., Chicago, IL, US
- CellTrans Inc., Chicago, IL, US
Prosecution history
- 20 Jun 2026 — NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
- 20 Jun 2026 — REGISTERED - SEC. 8 (6-YR) ACCEPTED
- 20 Jun 2026 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 09 Mar 2026 — TEAS SECTION 8 RECEIVED
- 18 Feb 2025 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 18 Feb 2020 — REGISTERED-PRINCIPAL REGISTER
- 14 Jan 2020 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 13 Jan 2020 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 13 Jan 2020 — STATEMENT OF USE PROCESSING COMPLETE
- 30 Dec 2019 — USE AMENDMENT FILED
- 09 Jan 2020 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 30 Dec 2019 — TEAS STATEMENT OF USE RECEIVED
- 30 Jul 2019 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 26 Jul 2019 — SOU EXTENSION 1 GRANTED
- 26 Jul 2019 — SOU EXTENSION 1 FILED